| The MLL recombinome of acute leukemias in 2013 C Meyer, J Hofmann, T Burmeister, D Gröger, TS Park, M Emerenciano, ... Leukemia 27 (11), 2165-2176, 2013 | 563 | 2013 |
| Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ... New England Journal of Medicine 386 (4), 351-363, 2022 | 406 | 2022 |
| Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 324 | 2018 |
| MYD88 L265P mutation in Waldenstrom macroglobulinemia S Poulain, C Roumier, A Decambron, A Renneville, C Herbaux, ... Blood, The Journal of the American Society of Hematology 121 (22), 4504-4511, 2013 | 274 | 2013 |
| Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib D Ghez, A Calleja, C Protin, M Baron, MP Ledoux, G Damaj, M Dupont, ... Blood, The Journal of the American Society of Hematology 131 (17), 1955-1959, 2018 | 254 | 2018 |
| Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma C Herbaux, J Gauthier, P Brice, E Drumez, L Ysebaert, H Doyen, ... Blood, The Journal of the American Society of Hematology 129 (18), 2471-2478, 2017 | 245 | 2017 |
| Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study N Delanoy, JM Michot, T Comont, N Kramkimel, J Lazarovici, R Dupont, ... The Lancet Haematology 6 (1), e48-e57, 2019 | 218 | 2019 |
| Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia S Poulain, C Roumier, A Venet-Caillault, M Figeac, C Herbaux, G Marot, ... Clinical Cancer Research 22 (6), 1480-1488, 2016 | 118 | 2016 |
| Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group E Tchernonog, P Faurie, P Coppo, H Monjanel, A Bonnet, MA Génin, ... Annals of Oncology 28 (4), 843-848, 2017 | 109 | 2017 |
| Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial S Le Gouill, F Morschhauser, D Chiron, K Bouabdallah, G Cartron, ... Blood, The Journal of the American Society of Hematology 137 (7), 877-887, 2021 | 100 | 2021 |
| Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers C Rossi, J Gilhodes, M Maerevoet, C Herbaux, F Morschhauser, P Brice, ... American journal of hematology 93 (8), 1042-1049, 2018 | 94 | 2018 |
| Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil C Herbaux, R Merryman, S Devine, P Armand, R Houot, F Morschhauser, ... Blood, The Journal of the American Society of Hematology 132 (1), 9-16, 2018 | 85 | 2018 |
| MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome S Poulain, EM Boyle, C Roumier, H Demarquette, M Wemeau, S Geffroy, ... British journal of haematology 167 (4), 506-513, 2014 | 85 | 2014 |
| Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study C Buske, A Tedeschi, J Trotman, R García-Sanz, D MacDonald, ... Journal of Clinical Oncology 40 (1), 52, 2022 | 82 | 2022 |
| Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA C Sarkozy, C Copie-Bergman, D Damotte, S Ben-Neriah, B Burroni, ... The American Journal of Surgical Pathology 43 (3), 341-351, 2019 | 72 | 2019 |
| TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia S Poulain, C Roumier, E Bertrand, A Renneville, A Caillault-Venet, ... Clinical Cancer Research 23 (20), 6325-6335, 2017 | 69 | 2017 |
| Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma G Fouquet, S Guidez, C Herbaux, Z Van de Wyngaert, S Bonnet, ... Clinical Cancer Research 20 (12), 3254-3260, 2014 | 69 | 2014 |
| Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma J Timmerman, C Herbaux, V Ribrag, AD Zelenetz, R Houot, SS Neelapu, ... American journal of hematology 95 (5), 510-520, 2020 | 64 | 2020 |
| A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features C Sarkozy, F Morschhauser, S Dubois, T Molina, JM Michot, ... Clinical Cancer Research 26 (13), 3145-3153, 2020 | 63 | 2020 |
| Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule, EA Kio, L Karlin, ... Clinical Cancer Research 26 (12), 2810-2818, 2020 | 59 | 2020 |
